Drug intelligence / Profile preview

anlotinib + niraparib + osimertinib

Development stage: Preclinical
Lead developer: Nanjing Chia-Tai Tianqing Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of anlotinib (a multi-target tyrosine kinase inhibitor), niraparib (a PARP inhibitor), and osimertinib (a third-generation EGFR-TKI). This combination is being investigated for its potential to overcome drug resistance in cancer treatment, particularly in non-small cell lung cancer (NSCLC) and ovarian cancer. Anlotinib targets VEGFR, FGFR, PDGFR, and c-Kit, while niraparib inhibits PARP enzymes, and osimertinib targets EGFR mutations.

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)TNKS (Poly(ADP-ribose) Polymerase 5a)PARP3 (Poly(adp-ribose) polymerase 3)VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR3 (Vascular endothelial growth factor receptor 3)PDGFRA (Platelet-derived growth factor receptor alpha)FGFR (FGFR family)RET (Rearranged during transfection receptor tyrosine kinase)PARP2 (Poly (adp-ribose) polymerase 2)

Beyond the preview

Go deeper on anlotinib + niraparib + osimertinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anlotinib + niraparib + osimertinib.

Explore the full profile